Well, all SHs should be backing this...
"If the Phase 3 trial results confirm the earlier Phase 2 data, where we saw improvements in patient function as well as reductions in hospitalizations and deaths, this important technology will transform cardiovascular care and would provide a powerful new treatment for advanced heart failure.”
From the SP point of view, we took a significant hit with the LVAD annc with CHF's worth (and other indications) wiped out, but this to me if full steam ahead with CHF.
So I'm happy with the news and lets move on!
Onwards and upwards
Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-16
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.035(3.11%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.131M | 3.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 19749 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 51160 | 31 |
View Market Depth
| Last trade - 15.54pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |